AiVF
fund manager
sector
Healthcare
geography
Rest of world
Vintages
status
Portfolio
category
#A must-have

AiVF

Co-invested company
AiVF is revolutionizing in vitro fertilization (IVF) by using artificial intelligence to improve the outcomes and efficiency of fertility clinics. Its EMA platform evaluates embryos 50 times faster and with increased accuracy compared to a human embryologist, helping to help couples start a family.
Photo of a child representing AiVF, part of the Private Equity manager's portfolio Insight Partners

AiVF key figures

2018
year established
1 bn
expected births via IVF by 2099
98%
faster to detect problems in embryos than traditional methods
60
employees
Data at
4/10/24
*Source: Public data from company websites and social networks. For the most up-to-date information, we invite our investors to consult the reports available in their own space.

About AiVF

Thanks to the use of artificial intelligence, Israeli company AiVF has developed the latest generation of in vitro fertilization (IVF) techniques, meeting a growing need in the fertility field.

Since the first IVF baby was born in 1978, this technology has brought millions of children into the world. However, current methods are often costly and cannot keep pace with growing demand. Projections indicate that by the end of the 21st century, one billion children could be born thanks to IVF.

Founded by embryologist Daniella Gilboa and fertility professor Daniel Seidman, AiVF was created in response to these challenges. Initially conceived as a thesis topic, the idea was to combine clinical embryology and data science. Thus was born EMA, the world's first platform based entirely on artificial intelligence, using machine learning and computer-aided vision algorithms.

This platform reduces the time to conception, increases predictability and improves success rates. By automating data and establishing standardized procedures, clinics can speed up the IVF process, while ensuring patient well-being.

The results are impressive: in clinics using this technology in Europe and the USA, the EMA platform is 50 times faster and 48% more accurate than a human embryologist.

As Daniella Gilboa explains, "our vision is to help people realize their dream of starting a family. We provide innovative solutions in the field of fertility, while contributing to the future of reproductive medicine".

In the same sector as AiVF

Company videos
No items found.
Discover our exclusive services
Insight Partners
Odyssey 2021
Odyssey 2021
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio